ALKS 3831: Completed Phase II enrollment

Alkermes completed enrollment of 309 patients with schizophrenia in a double-blind, international Phase II trial comparing 3 dose levels of oral ALKS 3831 once daily for 12 weeks plus olanzapine vs. p...